EU, Medical Director, Hematology

Updated: June 14, 2024 11:08 AM GMT

GSK

Brentford

Site Name: Baar Onyx, GSK House

Posted Date: Jun 13 2024

Overview

Medical Affairs is a critical bridge between R&D and the commercial organization to ensure that our medicines reach the appropriate patients. GSK has committed to building a new oncology business, with initial focus on selected EU markets. To this end, this is a critical role to ensure hematology/oncology resource and activities are aligned and deployed to business priorities in the EU region.

Hematology is a focus area with a key asset in Multiple Myeloma expected to grow potentially to GSK’s flagship product based on potential line-extensions once data from additional phase III trials will read out in 2023.

Medical Affairs needs to build additional scientific leadership to provide greater insights and significant external presence to support and lead GSK’s hematology portfolio in Europe.

The EU Medical Director, Hematology is the go-to person for this Multiple Myeloma asset in Europe, who possesses strong... More Detail